Skip to main content
Erschienen in: Osteoporosis International 8/2012

01.08.2012 | Opinion Paper

What’s in a name? What constitutes the clinical diagnosis of osteoporosis?

verfasst von: E. S. Siris, S. Boonen, P. J. Mitchell, J. Bilezikian, S. Silverman

Erschienen in: Osteoporosis International | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Osteoporosis is a skeletal disorder in which reductions in bone strength predispose to an increased risk for fractures. Currently, the diagnosis is officially made based exclusively on bone mineral density T-scores that are ≤−2.5 at the spine or hip. Limiting the clinical diagnosis of osteoporosis solely to a T-score-based criterion, which is the official convention in the USA, creates uncertainty about the use of the term osteoporosis to diagnose older women and men who have T-scores >−2.5, but either have already sustained low-trauma fractures or are recognized as having high fracture risk based on absolute fracture risk calculations from FRAX or other algorithms. A failure to diagnose such patients as having osteoporosis may be one component of the well-documented underdiagnosis and undertreatment of this disease which limits our ability to reduce the burden of fractures worldwide. There is a need to expand the criteria for making a clinical diagnosis and to codify these changes in order to help patients, physicians, policy makers, and payers better understand who has this disease and the elevated risk for fracture that it represents.
Literatur
1.
Zurück zum Zitat Klibanski A, Adams-Campbell L, Bassford T et al (2001) NIH consensus development panel on osteoporosis prevention, diagnosis and treatment. Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRef Klibanski A, Adams-Campbell L, Bassford T et al (2001) NIH consensus development panel on osteoporosis prevention, diagnosis and treatment. Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRef
2.
Zurück zum Zitat Siris ES, Chen Y, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112PubMedCrossRef Siris ES, Chen Y, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112PubMedCrossRef
3.
Zurück zum Zitat Schuit SCE, van der Klift M, Weel AEAM et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202PubMedCrossRef Schuit SCE, van der Klift M, Weel AEAM et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202PubMedCrossRef
4.
Zurück zum Zitat Wainwright SA, Marshall LM, Ensrud KE et al (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90:2787–2793PubMedCrossRef Wainwright SA, Marshall LM, Ensrud KE et al (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90:2787–2793PubMedCrossRef
5.
Zurück zum Zitat Kanis J (2008) Assessment of osteoporosis at the primary healthcare level. WHO Collaborating Centre, University of Sheffield, Sheffield Kanis J (2008) Assessment of osteoporosis at the primary healthcare level. WHO Collaborating Centre, University of Sheffield, Sheffield
7.
Zurück zum Zitat Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedCrossRef Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedCrossRef
8.
Zurück zum Zitat Lindsay R, Silverman SL, Cooper C et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320–323PubMedCrossRef Lindsay R, Silverman SL, Cooper C et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320–323PubMedCrossRef
9.
Zurück zum Zitat Gehlbach S, Saag KG, Adachi JD et al (2012) Previous fractures at multiple sites increase the risk for subsequent fractures: the global longitudinal study of osteoporosis in women. J Bone Miner Res 27:645–653PubMedCrossRef Gehlbach S, Saag KG, Adachi JD et al (2012) Previous fractures at multiple sites increase the risk for subsequent fractures: the global longitudinal study of osteoporosis in women. J Bone Miner Res 27:645–653PubMedCrossRef
10.
Zurück zum Zitat Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA (2007) Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Rel Res 461:226–230 Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA (2007) Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Rel Res 461:226–230
12.
Zurück zum Zitat Dawson-Hughes B, Looker AC, Tosteson ANA, Johansson H, Kanis JA, Melton LJ III (2012) The potential impact of the national osteoporosis foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008. Osteoporos Int 23:811–820PubMedCrossRef Dawson-Hughes B, Looker AC, Tosteson ANA, Johansson H, Kanis JA, Melton LJ III (2012) The potential impact of the national osteoporosis foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008. Osteoporos Int 23:811–820PubMedCrossRef
13.
Zurück zum Zitat Eisman J, Clapham S, Kehoe L (2004) Osteoporosis prevalence and levels of treatment in primary care: the Australian Bone Care Study. J Bone Miner Res 19:1969–1975PubMedCrossRef Eisman J, Clapham S, Kehoe L (2004) Osteoporosis prevalence and levels of treatment in primary care: the Australian Bone Care Study. J Bone Miner Res 19:1969–1975PubMedCrossRef
14.
Zurück zum Zitat Marsh D, Akesson K, Beaton DE et al (2011) Coordinator based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22:2051–2065PubMedCrossRef Marsh D, Akesson K, Beaton DE et al (2011) Coordinator based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22:2051–2065PubMedCrossRef
15.
Zurück zum Zitat Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for the treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for the treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef
16.
Zurück zum Zitat Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRef Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRef
17.
Zurück zum Zitat Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef
18.
Zurück zum Zitat Ryder KM, Cummings SR, Palermo L et al (2008) Does a history of non-vertebral fracture identify women with osteoporosis for treatment? J Gen Intern Med 23:1177–1181PubMedCrossRef Ryder KM, Cummings SR, Palermo L et al (2008) Does a history of non-vertebral fracture identify women with osteoporosis for treatment? J Gen Intern Med 23:1177–1181PubMedCrossRef
19.
Zurück zum Zitat Siris ES, Simon JA, Barton IP, McClung MR, Grauer A (2008) Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int 19:681–686PubMedCrossRef Siris ES, Simon JA, Barton IP, McClung MR, Grauer A (2008) Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int 19:681–686PubMedCrossRef
20.
Zurück zum Zitat Kanis JA, Johnell O, Black DM et al (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 33:293–300PubMedCrossRef Kanis JA, Johnell O, Black DM et al (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 33:293–300PubMedCrossRef
21.
Zurück zum Zitat McCloskey EV, Johansson H, Oden A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811–817PubMedCrossRef McCloskey EV, Johansson H, Oden A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811–817PubMedCrossRef
22.
Zurück zum Zitat Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049–1054PubMedCrossRef Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049–1054PubMedCrossRef
23.
Zurück zum Zitat McCloskey EV, Johansson H, Oden A et al (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res. doi:10.1002/jbmr.1606 McCloskey EV, Johansson H, Oden A et al (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res. doi:10.​1002/​jbmr.​1606
24.
Zurück zum Zitat Kanis JA, Johansson H, Oden A, McCloskey EV (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 47:729–735PubMedCrossRef Kanis JA, Johansson H, Oden A, McCloskey EV (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 47:729–735PubMedCrossRef
25.
Zurück zum Zitat Donaldson MG, Palermo L, Ensrud K, Hochberg MC, Schousboe JT, Cummings SR (2012) Effect of alendronate for reducing fracture by FRAX Score and femoral neck BMD: The fracture Intervention Trial. J Bone Miner Res. doi:10.1002/jbmr.1625 Donaldson MG, Palermo L, Ensrud K, Hochberg MC, Schousboe JT, Cummings SR (2012) Effect of alendronate for reducing fracture by FRAX Score and femoral neck BMD: The fracture Intervention Trial. J Bone Miner Res. doi:10.​1002/​jbmr.​1625
Metadaten
Titel
What’s in a name? What constitutes the clinical diagnosis of osteoporosis?
verfasst von
E. S. Siris
S. Boonen
P. J. Mitchell
J. Bilezikian
S. Silverman
Publikationsdatum
01.08.2012
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 8/2012
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-012-1991-0

Weitere Artikel der Ausgabe 8/2012

Osteoporosis International 8/2012 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.